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Background: Fractional exhaled nitric oxide (FENO) is a marker of airway inflammation in
asthma. Monitoring of such inflammation is currently not included in asthma guidelines and
remains controversial. The hypothesis underlying the present study was that, FENO could help
assessing asthma control and, therefore, improve its management, by predicting loss of control
in asthmatics.
Methods: A total of 90 adult asthmatics were included in the study. Asthma control was eval-
uated according to ACQ. All patients underwent FENO by chemiluminescent (EndoNO) and
hand-held (MINO) devices, followed by lung function testing.
Results: MINO was accurate as compared to EndoNO. FENO was significantly increased in
uncontrolled as compared to controlled asthmatics using both devices. FENO measurement
was able to predict control maintenance in controlled asthmatics in the absence of any change
in their treatment. Indeed, using cut-off values of 31 and 40 ppb, the negative predictive
values were 95 and 97% for EndoNO and MINO, respectively. EndoNO and MINO were also able
to assess asthma control, although to a lesser extent.Exploration Fonctionnelle Respiratoire, Hoˆpital du Haut-Le´ve`que, CHU de Bordeaux, Avenue de
l.: þ33 5 57 65 65 13; fax: þ33 5 57 65 60.
-bordeaux2.fr (A. Ozier), pierre-olivier.girodet@pharmaco.u-bordeaux2.fr (P.-O. Girodet), imane_
tunondelara@chu-bordeaux.fr (J.-M. Tunon de Lara), roger.marthan@u-bordeaux2.fr (R. Marthan),
rger).
1 Elsevier Ltd. All rights reserved.
990 A. Ozier et al.Conclusions: These findings suggest that FENO can predict the persistence of asthma control in
controlled patients and may now be used in asthma management since it can accurately be
measured by means of hand-held devices.
ª 2011 Elsevier Ltd. All rights reserved.Figure 1 Flow-chart of study design. Visits 1 and 2 included
the assessment of asthma control questionnaire (ACQ), fraction
of exhaled NO (FENO) and pulmonary function test (PFT).
Phone ACQ was only assessed in controlled patients with stable
treatment 3 weeks after visit 1 or 2.Introduction
Asthma is an increasingly prevalent disease characterised by
bronchial hyperresponsiveness, bronchial inflammation and
remodelling.1,2 Since airway inflammation is a key feature of
asthma,3 a wide range of inflammatory biomarkers has been
actively examined. Airway inflammation can be assessed
noninvasively, by means of various techniques including
collecting exhaled breath condensate, counting the sputum
eosinophils or measuring fractional exhaled nitric oxide
(FENO).
4 Assessed initially by means of chemiluminescence
devices, FENO is considered as a surrogate marker of eosin-
ophilic airway inflammation that correlateswell with sputum
eosinophils.5 FENO is noninvasively measured, provides
immediate and reproducible results and is associated with
ahighdegreeof acceptancebypatients.However, stationary
chemiluminescence devices are not widely used in clinical
practicebecauseof high cost, bulkyequipment, requirement
for daily calibration and technical maintenance, and are
restricted to specialised laboratories and secondary care
institutions. The development of hand-held FENO monitors
based on an electrochemical technique now allows clinicians
to more easily monitor FENO. Indeed, such measurements
were found reproducible and in agreement with che-
miluminescence devices.6,7
In asthma, FENO has been proposed not only to assess
inflammation, but also to verify adherence therapy8 and to
guide and monitor response to steroids.9e11 Nevertheless,
FENO monitoring is not yet included in current asthma guide-
lines12 and its interest remains controversial. Doses of inhaled
corticosteroids (ICS) have been successfully reduced without
compromising asthma control, when the main treatment
strategy was based on FENO in one study,
9 although such an
effect has not been confirmed.13e15 These conflicting results
may be related to the discordance between symptoms and
airway inflammation in some patients as shown by cluster
analysis.16 Furthermore, elevated FENO has been shown to
correlate with subsequent deterioration in asthma con-
trol,17,18 but controversial results have also been reported on
this issue.19e21 For instance, a correlation between FENO and
asthma control appeared to be limited to steroid naı¨ve
patients.20 Indeed, prediction of steroidwithdrawal failure by
FENO is controversial.
17,19 By contrast, in uncontrolled diffi-
cult-to-treat asthmatics, FENO seemed to predict the res-
ponse to corticosteroids.11 Anyhow, there is no available
information in controlled asthmatic population, regarding the
interest of FENO in predicting a loss of control.
The hypothesis addressed in the present study was that,
FENO measurement could help assessing asthma control and
improve its management, by predicting loss of control in
controlled asthmatics in clinical practice. Therefore, the
aims of this study were, (i) to appraise the potential of
MINO device as compared to another established laboratory
chemiluminescence analyser, as a tool for assessing asthmacontrol and (ii) to predict loss of control in a cohort of
controlled adult asthmatic patients.
Material and methods
Study population
A total of 90 adult asthmatic patients were prospectively
recruited from January 2009 to January 2010 as outpatients
in the “Centre Hospitalier Universitaire, Service des Ma-
ladies Respiratoires” of Bordeaux (Visit 1, Fig. 1). Asth-
matics were enrolled using the following inclusion criteria:
patients >18 years had to exhibit characteristic symptoms
(i.e., wheezing and breathlessness), as well as a history of
bronchial hyperresponsiveness confirmed within the 2 pre-
vious years either by a significant improvement by >12% in
the forced expiratory volume in 1 s (FEV1) 10 min after the
inhalation of 200 mg of salbutamol,12 or a provocative
concentration of methacholine required to lower the FEV1
by 20% (PC20) of <4 mg/ml according to the American
Thoracic Society (ATS) criteria.22 Non-inclusion criteria
were not applied in patients’ selection.
Exhaled NO can predict maintenance of asthma control 991For each patient, age, body mass index (BMI), tobacco,
atopic status, mean duration of the disease, asthma control
questionnaire (ACQ23), treatments and lung function tes-
ting data using body plethysmography, were collected at
Visit 1. Regarding the ACQ, the 6 clinical items and the
functional item (each quoted from 0 to 6) were equally
weighted and averaged. Patients were graded according to
their level of asthma control as controlled (i.e. ACQ < 1.5)
or uncontrolled patients (i.e. ACQ  1.5).23 Patients were
also graded as severe or non severe asthma according to the
ATS Guidelines.24
Since the study was focused on controlled asthmatics
and in order to avoid the effect of change in asthma
medication, we excluded the 16 controlled asthmatics with
change in their asthma treatment (Fig. 1). For the 46
controlled patients at Visit 1 without any change in their
asthma treatment, loss of control was systematically eval-
uated 3 weeks after the inclusion, by phone using the
following criteria: an increase of more than 0.518 in
the mean 6 clinical ACQ items as used by Mahut et al.,21 the
need for a course of oral corticosteroid, the presence of
unscheduled visit or hospitalisation for asthma.
The 28 uncontrolled patients at Visit 1 were reassessed
identically 3e6 months later (Visit 2, Fig. 1), after treat-
ment adjustment according to Global Initiative for
Asthma’s (GINA) guidelines.12 The 19 patients who re-
mained uncontrolled after six months were excluded,
whereas the 9 finally controlled patients were then fol-
lowed for 3 weeks without any change in their asthmaTable 1 Patients’ characteristics according to asthma control.
Controlled asthma
(ACQ < 1.5)
Subjects (n) 62
F/M 42/20
Age (yr) 38.5  2.1
BMI (kg/m2) 24.7  0.7
Atopic, n (%) 48 (77.4)
Disease duration (yr) 19  1.5
Current/ex/non-smokers (n) 8/6/48
Pack years 2.5  1.0
Current ICS dose, n (mg eq BDP/day) 48 (964  131.4)
Oral steroid, n (mg/day) 3 (30.0  15.3)
LABA, n (%) 31 (50.0)
ACQ score 0.62  0.06
FEV1 (% predicted) 92.1  2.1
FEV1 (L) 2.9  0.1
FEV1/FVC (%) 78.0  1.3
FEF25e75 (% predicted) 71.9  3.4
FEF25e75 (L) 2.8  0.2
RV (% predicted) 104.0  3.3
RV (L) 1.8  0.1
TLC (% predicted) 101.6  1.9
TLC (L) 5.6  0.2
Values are presented as mean  SEM. Abbreviations: ACQ: asthma con
mass index; FEF25e75: forced midexpiratory flow rate; FEV1: forced
capacity; ICS: inhaled corticosteroids; LABA: long-acting b2-agonist;
dicted: from the normative references of pulmonary function tests (Q
obtained when comparing controlled versus uncontrolled asthmatics,treatment. As for the previous group, loss of control was
assessed by a phone ACQ.
All patients gave their informed consent to participate in
the study, after the nature of the procedure had been fully
explained. The study followed recommendations outlined
in the Helsinki Declaration and received approval from the
local ethics committee.
Exhaled nitric oxide measurement
FENO was measured before plethysmography using the
chemiluminescence device EndoNO (SERES, France) on-line
at a flow rate of 50 ml/s and a pressure of 10 cm H2O
according to the European Respiratory Society/American
Thoracic Society recommendations.25 For each patient, 3
technically adequate measurements were performed with
a sustained plateau of at least 10 s, and the arithmetic
mean FENO was calculated with a coefficient of variation of
less than 10%. Alveolar NO concentrations (FANO) and
bronchial NO flux (J’aw) were calculated using various
expiratory flow rates according to Tsoukias and George
model.26 Since FANO can be artificially increased by bron-
chial NO back-diffusion into the alveolar space, we applied
the correction proposed by P. Condorelli et al.27 The ana-
lyser was calibrated daily.
Similarly, FENOwasalsomeasuredbeforeplethysmography
using the electrochemical device NIOX MINO (Aerocrine AB,
Sweden). As previously described, a single measurement
was acquired according to the manufacturer’s instructionUncontrolled asthma
(ACQ  1.5)
p values (Wilcoxon)
28
15/13 0.20
44.8  3.2 0.06
26.8  1.4 0.18
23 (82.1) 0.61
22  3.2 0.52
3/6/19
3.0  1.1 0.29
17 (789  179.8) 0.34
3 (23.3  8.8) 0.82
14 (50.0) 1.00
2.48  0.17 < 0.001
75.2  4.3 < 0.001
2.3  0.1 0.007
68.5  2.3 0.001
49.8  5.1 < 0.001
1.9  0.2 0.003
107.4  4.7 0.73
2.0  0.1 0.20
96.7  2.8 0.31
5.5  0.2 0.94
trol questionnaire; BDP: beclomethasone dipropionate; BMI: body
expiratory volume in 1 s; F/M: female/male; FVC: forced vital
RV: residual volume; TLC: total lung capacity; yr: years; % pre-
uanjer et al., Eur Respir J Suppl. 1993; 16: 5e40). P values were
using Wilcoxon rank-sum tests.
Figure 2 Exhaled nitric oxide is increased in uncontrolled asthmatics. Box plots show nitric oxide (NO) measurements assessed
using EndoNO (A, C, D) and MINO (B). Box plots summarise medians with 25% and 75% interquartiles. Error bars represent 5th and
95th percentiles. Circles represent upper and lower outliers. )p < 0.05 using Wilcoxon rank-sum tests. ppb: parts per billion.
992 A. Ozier et al.with identical mouth flow rate and pressure settings.7 The
sensor of theMINO devicewas not change during the course of
the study.
Statistical analysis
Comparisons of clinical, functional and FENO data between
groups were performed bymeans ofWilcoxon rank-sum tests.
Inter-devices agreement of NO measurement was eval-
uated on log-transformed data in order to normalise the
distribution. According to Bland and Altman analysis,28 weTable 2 Correlation between NO measurements and clinical or
EndoNO
FENO Ja
Age (yr) 0.06 (0.60) 
BMI (kg/m2) 0.002 (0.98)
Disease duration (yr) 0.03 (0.77) 
ICS dose (mg eq BDP/day) 0.02 (0.86) 
Oral steroid (mg/day) 0.12 (0.26) 
ACQ score 0.10 (0.38)
FEV1 (% predicted) 0.03 (0.77)
FEV1/FVC (%) 0.04 (0.75) 
FEF25e75 (% predicted) 0.06 (0.63)
RV (% predicted) 0.03 (0.81) 
TLC (% predicted) 0.06 (0.59) 
Values are Pearson correlation coefficients (with p values in parenthes
asthma control questionnaire; BDP: beclomethasone dipropionate;
FEF25e75: forced midexpiratory flow rate; FENO: fraction of exhaled ni
capacity; Jaw: bronchial flow of NO; ICS: inhaled corticosteroids; LA
capacity.analysed (i) Pearson’s correlation coefficient, (ii) means of
both measurements plotted against their differences, (iii)
lack of agreement (i.e. bias estimated by the mean
difference and the standard deviation of the mean), and
(iv) error measurement between the two devices (i.e.
defined by Sw Z within subject standard deviation). Log-
transformed FENO data from the 2 devices were compared
by paired Student’s t-tests.
Correlations between log-transformed FENO data and
clinical functional parameters were assessed using Pear-
son’s correlation coefficients.functional parameters.
MINO
w FANO FENO
0.07 (0.47) 0.02 (0.88) 0.02 (0.89)
0.03 (0.76) 0.08 (0.48) 0.07 (0.54)
0.01 (0.93) 0.10 (0.35) 0.16 (0.16)
0.07 (0.56) 0.19 (0.09) 0.04 (0.75)
0.18 (0.09) 0.09 (0.40) 0.04 (0.71)
0.10 (0.38) <0.01 (0.99) 0.07 (0.54)
0.06 (0.59) 0.06 (0.59) 0.07 (0.52)
0.02 (0.90) 0.10 (0.38) 0.05 (0.67)
0.09 (0.46) 0.07 (0.54) 0.07 (0.57)
0.01 (0.93) 0.04 (0.76) 0.06 (0.59)
0.15 (0.21) 0.12 (0.31) 0.05 (0.63)
es) using log-transformed NO measurements. Abbreviations: ACQ:
BMI: body mass index; FANO: fraction of alveolar nitric oxide;
tric oxide; FEV1: forced expiratory volume in 1 s; FVC: forced vital
BA: long-acting b2-agonist; RV: residual volume; TLC: total lung
Figure 3 Receiver-operator characteristic (ROC) curve ana-
lysis for EndoNO and MINO’s exhaled nitric oxide measurements
to assess asthma control. ROC curves determine the effective-
ness of EndoNO (nZ 89, black solid line) and MINO (nZ 78, grey
dashed-dotted line) to assess uncontrolled asthma according to
asthma control questionnaire (ACQ  1.5).
Exhaled NO can predict maintenance of asthma control 993Receiver operating characteristic (ROC) curves were
constructed using both the raw FENO data and asthma
control or loss of control. The area under the curve (AUC)
for each device was compared to 0.5. A positive likelihood
ratio [LR(þ)] was calculated as sensitivity/(1specificity).
A negative likelihood ratio [LR()] was calculated as
(1  sensitivity)/specificity.
Chi square tests were used to compare the percentage
of loss of control between patients with FENO above and
below the threshold. All analyses were performed using
NCSS software (NCSS 2001, Kaysville, UT, USA). Results
were considered statistically significant when p < 0.05.
Results
Interest of NO measurement in the assessment of
asthma control
Clinical and functional characteristics of all patients are
shown in Table 1 (See also Supplemental Fig. 1 and
Supplemental Table 1). FENO was significantly increased
in uncontrolled as compared to controlled asthmatics using
either EndoNO or MINO (Fig. 2A and B). Similar results were
obtained when measuring bronchial NO (Fig. 2C), whereas
no significant difference was found in terms of FANO
(Fig. 2D).
There was no correlation between NO measurements
and ACQ scores, or any other clinical or functional
parameters (Table 2). We then performed a ROC curve
analysis to determine the effectiveness of both EndoNOTable 3 Effectiveness of NO measurements in the assessment o
Prevalence Se Sp PPV
EndoNO 30.3 77.7 62.9 47.7
MINO 32.1 60.0 66.0 45.4
Effectiveness of NO measurements was determined in 89 subjects (En
oxide fraction of 22 ppb and 31 ppb for EndoNO and MINO, respectively
to ACQ (i.e ACQ  1.5). Values are presented as percentages, unless
LR(þ): positive likelihood ratio; LR(): negative likelihood ratio; NP
sensitivity; Sp: specificity. p values represented the statistical significand MINO in assessing asthma control according to ACQ
(Fig. 3). Both devices were indeed effective since the area
under the curve was significantly different from 0.5 (Table
3). The highest sum of sensitivity and specificity for
EndoNO was obtained using a threshold value of 22 ppb.
For MINO, the cut-off value had to be increased up to
31 ppb to obtain the best control assessment (Table 3).
Since the positive predictive value of both EndoNO and
MINO to predict uncontrolled asthma was lower than 50%,
we thus hypothesised that, FENO would be more effective
to predict a loss of asthma control in already controlled
patients.
NO measurement predicted the persistence of
asthma control in controlled patients
We followed up the 55 controlled patients without any
change in their asthma treatment and reassessed asthma
control after 3 weeks. We then performed new ROC curve
analyses to determine the effectiveness of both EndoNO
and MINO to predict loss of asthma control (Fig. 4A). Both
devices were more effective to predict a loss of asthma
control (Table 4). Indeed, using the new best thresholds for
both EndoNO and MINO (i.e. 31 ppb and 40 ppb respec-
tively), we were able to predict a loss of asthma control in
67% and 60% of controlled asthmatics, respectively. More
interestingly, the negative predictive values were higher
than 95% with relevant likelihood ratios for both devices
(Table 4). That is patients below the thresholds remained
controlled without any change in their treatment. The
proportion of patients that turned to be not controlled was
significantly lower when FENO was below the thresholds
than when FENO was above the thresholds (Fig. 4B).
Accuracy of MINO measurements
We analysed the accuracy of MINO according to Bland and
Altman analysis (Supplemental Fig. 2). There was a strong
correlation between the 2 devices (Supplemental Fig. 2A).
However, FENO values measured by MINO device were
significantly higher than those by EndoNO (p < 0.0001,
paired t-test). As a consequence, the mean difference
between MINO and EndoNO measurements was positive
(Supplemental Fig. 2B) and the error measurement Sw was
estimated to be 9 ppb. However, there was no correlation
between the mean and the difference between the 2
devices providing that MINO device was accurate
(Supplemental Fig. 2B).f uncontrolled asthma.
NPV LR(þ) LR() AUC (p values)
86.7 2.10 0.35 0.74 (<0.001)
77.8 1.77 0.61 0.64 (0.021)
doNO) and 78 subjects (MINO) using thresholds of exhaled nitric
. A positive case was defined as an uncontrolled asthma according
for both LR and AUC. Abbreviations: AUC: area under the curve;
V: negative predictive value; PPV: positive predictive value; Se:
ance of rejecting the AUC Z 0.5.
Figure 4 Effectiveness of exhaled nitric oxide measurements
to predict a loss of asthma control. A: Receiver-operator
characteristic (ROC) curves determine the effectiveness of
EndoNO (n Z 55, black solid line) and MINO (n Z 40, grey
dashed-dotted line) to predict a loss of asthma control in
controlled asthmatics (ACQ<1.5). B: Bars represent the
percentages of a loss of control within 3 weeks in controlled
asthmatics. )p < 0.05 using chi square tests.
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This study demonstrates, for the first time, that, FENO
measurement performed with either EndoNO or MINO,
allows predicting the persistence of control in already
controlled asthmatics. MINO was accurate as compared to
EndoNO, a referenced electrochemical device and may thus
be used in asthma management in clinical practice.
We hypothesised that FENO would be useful to predict
a loss of control in controlled asthmatics. In this study, we
demonstrated that more than 60% of patients lost their
control when FENO was above a defined threshold.
However, FENO was even better to predict control main-
tenance in this population. Jones et al. previously aimed at
predicting a loss of control after steroid withdrawal using
FENO measurement.
17 Whereas their positive predictive
value was adequate (i.e. 88%), their sensitivity and nega-
tive predictive values were poor (i.e. 25% for both).17
Conversely, in our study, the positive predictive value wasTable 4 Effectiveness of NO measurements in the assessment
Prevalence Se Sp PPV
EndoNO 18.2 80.0 91.1 66.7
MINO 17.5 85.7 87.8 60.0
Effectiveness of NO measurements was determined in 55 and 40 contro
31 ppb and 40 ppb for EndoNO and MINO, respectively. A positive c
presented as percentages, unless for both LR and AUC. Abbreviations:
negative likelihood ratio; NPV: negative predictive value; PPV: positi
resented the statistical significance of rejecting the AUC Z 0.5.indeed lower (i.e. 67% using EndoNO and 60% using MINO)
but both the sensitivity (i.e. 80% with EndoNO and 86% with
MINO) and the negative predictive values (i.e. 95% with
EndoNO and 97% with MINO) were dramatically higher.
However, steroid treatment was unchanged in our patients,
in agreement with recent GINA guidelines in controlled
patients.12 Michils et al. also aimed at predicting loss of
asthma control.18 However, they used an amplitude of FENO
change of more than 30% as a marker of worsening
asthma.18 In our study, we were able to predict a loss of
control using a single measurement, which may prove more
relevant in clinical practice. Perez de Llano et al. very
recently described a cut-off value of 30 ppb for MINO to
predict a positive response to oral steroid in difficult-to-
treat asthmatics.11 Collectively, these results suggest that
FENO could be useful for monitoring asthma treatment.
Besides, asthma management based on MINO FENO mea-
surements alone was found less costly than that based on
standard guidelines and seemed to provide similar health
benefits.29 On another way, the ability of FANO to predict
loss of asthma control within the same population was not
statistically significant (data not shown). Conversely, FANO
was significantly increased in severe asthmatics as
compared to non severe asthmatics, as previously demon-
strated earlier.18,30
When assessing the accuracy of MINO as compared to
EndoNO, data obtained by both devices were highly corre-
lated. According to Bland and Altman analysis, the mean of
both devices was not correlated with the difference sug-
gesting that MINO was accurate. Similar findings have
been previously obtained using other chemiluminescent
devices.6,7 However, in these studies, the chemilumines-
cent device was from the same manufacturer (i.e.
Aerocrine).6,7 In addition, we determined the error mea-
surement (i.e. Sw) according to Bland and Altman analysis.
As compared to EndoNO, we found that MINO over-
estimated FENO by 9 ppb.
We also test the ability of both EndoNO and MINO to
predict asthma control. A first result was that, FENO was
significantly increased in uncontrolled as compared to
controlled asthmatics and this finding deserves further
discussion. Indeed, very recently, Mahut et al. evaluated
FENO using EndoNO in controlled and uncontrolled asth-
matic patients using the same cut-off ACQ scores,21 but
they failed to show any difference between these 2 groups.
However, in our study, only adult asthmatics were enrolled,
whereas in that of Mahut et al., both children and adults
were followed up.21 Moreover, uncontrolled asthmatics
from our study presented higher ACQ scores, and thereforeof a loss of optimal asthma control.
NPV LR(þ) LR() AUC (p values)
95.3 9.00 0.21 0.90 (<0.001)
96.7 7.07 0.16 0.86 (<0.001)
lled asthmatics using thresholds of exhaled nitric oxide fraction of
ase was defined as a loss of optimal asthma control. Values are
AUC: area under the curve; LR(þ): positive likelihood ratio; LR():
ve predictive value; Se: sensitivity; Sp: specificity. p values rep-
Exhaled NO can predict maintenance of asthma control 995more symptoms. Regarding now asthma control, Michils
et al. previously addressed this issue based on ACQ.18 Using
ROC curve analyses, they proposed a relatively high cut-off
value of 45 ppb to exclude well-controlled asthma with
a predictive value of 88%.18 In the present study, we
proposed a lower cut-off FENO value of 22 and 31 ppb for
EndoNO and MINO, respectively to discriminate between
controlled and uncontrolled asthma using the best sum of
sensitivity and specificity. However, population from the
Michils’ study was different with only persistent asthmatics
and more atopics. Anyhow, positive and negative predictive
values were more satisfactory to predict the persistence of
control in controlled patients than to assess asthma control
per se. In addition, assessing control using ACQ is more
obvious and cheaper than using NO measurement.
In conclusion, our study has demonstrated that FENO
measured by either EndoNO or MINO and analysed, taking
into account specific cut-off values, can predict the
persistence of asthma control in controlled patients. From
the present results, it may thus be suggested that cont-
rolled asthmatics exhibiting a FENO value above the
threshold (i.e. 31 ppb using EndoNO, or 40 ppb using MINO),
should be reassessed within the 3rd week with, at least, no
decrease in corticosteroids doses, whereas a decreased in
corticosteroids treatment could be undertaken in those
whose FENO value is below the threshold. Since FENO can
now be accurately measured by means of hand-held
devices, complementary studies are required to evaluate
the interest of this strategy in clinical practice.Acknowledgements
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